

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**(Use as many sheets as necessary)**

**Complete if Known**

<b>Application Number</b>	<b>09/965,697</b>
<b>Filing Date</b>	<b>9/27/2001</b>
<b>First Named Inventor</b>	<b>Dhadialla</b>
<b>Art Unit</b>	<b>1649</b>
<b>Examiner Name</b>	<b>Michael Brannock</b>
<b>Attorney Docket Number</b>	<b>A01115A</b>

Sheet	1	of	2
-------	---	----	---

## U. S. PATENT DOCUMENTS


[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/965,697
Filing Date	9/27/2001
First Named Inventor	Dhadialla
Art Unit	1649
Examiner Name	Michael Brannock
Attorney Docket Number	A01115A

Sheet	2	of	2
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
W		ABLORDEPEY et al., Is a Nitrogen Atom an Important Pharmacophoric Element in Sigma Ligand Binding? Bioorganic & Medicinal Chemistry (2000), 8(8), 2105-2111.	
		NASSIF-MAKKI et al. Bisquaternary Ligands of the Common Allosteric Site of M2 Acetylcholine Receptors: Search for the Minimum Essential Distances between the Pharmacophoric Elements. Journal of Medicinal Chemistry (1999), 42(5), 849-858.	
		MALASKA et al. Chemical modification of ring C of himbacine: discovery of a Pharmacophoric Element for M2-selectivity. Bioorganic & Medicinal Chemistry Letters (1995), 5(1), 61-6.	
		KOZIKOWSKI et al. Delineating the Pharmacophoric Elements of huperzine A: importance of the unsaturated three-carbon bridge to its AChE inhibitory activity. Journal of Medicinal Chemistry (1991), 34(12), 3399-402.	
		BELSHAW et al. Rational design of orthogonal receptor-ligand combinations. Angewandte Chemie, International Edition in English (1995), 34(19), 2129-32.	
		PIERCE et al. Computational binding studies of orthogonal cyclosporin-cyclophilin pairs. Angewandte Chemie, International Edition in English (1997), 36(13/14), 1466-1469.	
		PEET et al. Engineering Novel Specificities for Ligand-Activated Transcription in the nuclear Hormone Receptor RXR. Chemistry & Biology, 1998, 5, 1, 13-21.	
		HOLT et al. Functional Expression of Exogenous Proteins in Mammalian Sensory Hair Cells Infected with Adenoviral Vectors. J Neurophysiol. (1999), 81(4), 1881-8.	
		DOYLE et al. Journal of the American Chemical Society (2001), 123(46), 11367-11371.	
		Hoppe et al. Molecular Therapy (2000) 1(2), 159-164.	

Examiner Signature		Date Considered	4/2/06
--------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.